STOCK TITAN

[Form 4] ADMA Biologics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

ADMA Biologics COO & SVP, Compliance Kaitlin M. Kestenberg-Messina filed a Form 4 for an automatic share withholding event on 07/24/2025. Transaction code F shows 3,027 common shares were surrendered to the company at $17.31 per share to satisfy payroll-tax obligations triggered by the vesting of restricted stock units (RSUs); no shares were sold on the open market.

Post-transaction, the executive beneficially owns 487,398 ADMA shares, comprised of 192,874 fully vested shares and 294,524 unvested RSUs that vest quarterly through 2029, contingent on continued service.

  • The filing is a routine tax-settlement and does not reflect a discretionary reduction in ownership.
  • Share count outstanding is modestly reduced, but insider economic exposure is unchanged.

Kaitlin M. Kestenberg-Messina, COO e SVP Compliance di ADMA Biologics, ha presentato un Modulo 4 per un evento automatico di trattenuta azionaria il 24/07/2025. Il codice transazione F indica che sono state consegnate all'azienda 3.027 azioni ordinarie al prezzo di $17,31 ciascuna per soddisfare gli obblighi fiscali sul reddito derivanti dalla maturazione di unità azionarie vincolate (RSU); nessuna azione è stata venduta sul mercato aperto.

Dopo la transazione, l'esecutivo detiene beneficiariamente 487.398 azioni ADMA, di cui 192.874 azioni completamente maturate e 294.524 RSU non ancora maturate che maturano trimestralmente fino al 2029, condizionate alla continuazione del servizio.

  • La dichiarazione è una normale liquidazione fiscale e non rappresenta una riduzione discrezionale della proprietà.
  • Il numero di azioni in circolazione è leggermente diminuito, ma l'esposizione economica interna rimane invariata.

Kaitlin M. Kestenberg-Messina, COO y SVP de Cumplimiento de ADMA Biologics, presentó un Formulario 4 por un evento automático de retención de acciones el 24/07/2025. El código de transacción F indica que se entregaron a la empresa 3,027 acciones comunes a $17.31 por acción para cumplir con las obligaciones fiscales sobre la nómina derivadas de la consolidación de unidades de acciones restringidas (RSU); no se vendieron acciones en el mercado abierto.

Después de la transacción, el ejecutivo posee beneficiosamente 487,398 acciones de ADMA, compuestas por 192,874 acciones totalmente consolidadas y 294,524 RSU no consolidadas que se consolidan trimestralmente hasta 2029, condicionadas a la continuidad del servicio.

  • La presentación es una liquidación fiscal rutinaria y no refleja una reducción discrecional de la propiedad.
  • El número de acciones en circulación se reduce ligeramente, pero la exposición económica interna permanece sin cambios.

ADMA Biologics의 COO 겸 준법감시담당 수석부사장인 Kaitlin M. Kestenberg-Messina2025년 7월 24일에 자동 주식 원천징수 이벤트에 대한 Form 4를 제출했습니다. 거래 코드 F는 제한 주식 단위(RSU)의 권리 확정으로 인해 발생한 급여세 의무를 충족하기 위해 주당 $17.313,027주의 보통주가 회사에 반환되었음을 나타내며, 공개 시장에서 주식은 판매되지 않았습니다.

거래 후, 해당 임원은 487,398주 ADMA 주식을 실질적으로 보유하고 있으며, 이 중 192,874주는 완전히 권리 확정된 주식이고, 294,524주는 2029년까지 분기별로 권리 확정되는 미권리 RSU로 계속 근무 조건에 따라 확정됩니다.

  • 이번 제출은 일상적인 세금 정산이며 소유권의 임의 감소를 반영하지 않습니다.
  • 발행 주식 수는 약간 감소했으나 내부자의 경제적 노출은 변함이 없습니다.

Kaitlin M. Kestenberg-Messina, COO et SVP Conformité d'ADMA Biologics, a déposé un formulaire 4 pour un événement automatique de retenue d'actions le 24/07/2025. Le code de transaction F indique que 3 027 actions ordinaires ont été remises à la société au prix de 17,31 $ par action pour satisfaire aux obligations fiscales sur les salaires déclenchées par l'acquisition des unités d'actions restreintes (RSU) ; aucune action n'a été vendue sur le marché ouvert.

Après la transaction, le dirigeant détient effectivement 487 398 actions ADMA, comprenant 192 874 actions entièrement acquises et 294 524 RSU non acquises qui seront acquises trimestriellement jusqu'en 2029, sous réserve de la poursuite du service.

  • Le dépôt est un règlement fiscal de routine et ne reflète pas une réduction discrétionnaire de la propriété.
  • Le nombre d'actions en circulation est légèrement réduit, mais l'exposition économique des initiés reste inchangée.

Kaitlin M. Kestenberg-Messina, COO und SVP Compliance von ADMA Biologics, reichte am 24.07.2025 ein Formular 4 für ein automatisches Aktieneinbehaltungsereignis ein. Der Transaktionscode F zeigt, dass 3.027 Stammaktien zu je 17,31 $ an das Unternehmen zurückgegeben wurden, um die lohnsteuerlichen Verpflichtungen zu erfüllen, die durch die Vesting von Restricted Stock Units (RSUs) ausgelöst wurden; es wurden keine Aktien am offenen Markt verkauft.

Nach der Transaktion besitzt die Führungskraft wirtschaftlich 487.398 ADMA-Aktien, bestehend aus 192.874 vollständig unverfallbaren Aktien und 294.524 unverfallbaren RSUs, die bis 2029 vierteljährlich vesten, vorbehaltlich der fortgesetzten Dienstzeit.

  • Die Meldung ist eine routinemäßige Steuerabrechnung und stellt keine freiwillige Reduzierung des Eigentums dar.
  • Die Anzahl der ausstehenden Aktien wurde geringfügig reduziert, die wirtschaftliche Insider-Exponierung bleibt jedoch unverändert.
Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU tax withholding; neutral signal, insider keeps sizable stake.

The code F transaction merely covers withholding taxes on vested RSUs and does not indicate an intentional sale. Only 3,027 shares (≈0.6% of her total holdings) left the insider’s account, while 487k shares remain beneficially owned. Such filings are common and usually carry no market-moving information. Investors should focus instead on upcoming fundamentals (e.g., immunoglobulin demand and margin expansion) rather than this administrative entry.

Kaitlin M. Kestenberg-Messina, COO e SVP Compliance di ADMA Biologics, ha presentato un Modulo 4 per un evento automatico di trattenuta azionaria il 24/07/2025. Il codice transazione F indica che sono state consegnate all'azienda 3.027 azioni ordinarie al prezzo di $17,31 ciascuna per soddisfare gli obblighi fiscali sul reddito derivanti dalla maturazione di unità azionarie vincolate (RSU); nessuna azione è stata venduta sul mercato aperto.

Dopo la transazione, l'esecutivo detiene beneficiariamente 487.398 azioni ADMA, di cui 192.874 azioni completamente maturate e 294.524 RSU non ancora maturate che maturano trimestralmente fino al 2029, condizionate alla continuazione del servizio.

  • La dichiarazione è una normale liquidazione fiscale e non rappresenta una riduzione discrezionale della proprietà.
  • Il numero di azioni in circolazione è leggermente diminuito, ma l'esposizione economica interna rimane invariata.

Kaitlin M. Kestenberg-Messina, COO y SVP de Cumplimiento de ADMA Biologics, presentó un Formulario 4 por un evento automático de retención de acciones el 24/07/2025. El código de transacción F indica que se entregaron a la empresa 3,027 acciones comunes a $17.31 por acción para cumplir con las obligaciones fiscales sobre la nómina derivadas de la consolidación de unidades de acciones restringidas (RSU); no se vendieron acciones en el mercado abierto.

Después de la transacción, el ejecutivo posee beneficiosamente 487,398 acciones de ADMA, compuestas por 192,874 acciones totalmente consolidadas y 294,524 RSU no consolidadas que se consolidan trimestralmente hasta 2029, condicionadas a la continuidad del servicio.

  • La presentación es una liquidación fiscal rutinaria y no refleja una reducción discrecional de la propiedad.
  • El número de acciones en circulación se reduce ligeramente, pero la exposición económica interna permanece sin cambios.

ADMA Biologics의 COO 겸 준법감시담당 수석부사장인 Kaitlin M. Kestenberg-Messina2025년 7월 24일에 자동 주식 원천징수 이벤트에 대한 Form 4를 제출했습니다. 거래 코드 F는 제한 주식 단위(RSU)의 권리 확정으로 인해 발생한 급여세 의무를 충족하기 위해 주당 $17.313,027주의 보통주가 회사에 반환되었음을 나타내며, 공개 시장에서 주식은 판매되지 않았습니다.

거래 후, 해당 임원은 487,398주 ADMA 주식을 실질적으로 보유하고 있으며, 이 중 192,874주는 완전히 권리 확정된 주식이고, 294,524주는 2029년까지 분기별로 권리 확정되는 미권리 RSU로 계속 근무 조건에 따라 확정됩니다.

  • 이번 제출은 일상적인 세금 정산이며 소유권의 임의 감소를 반영하지 않습니다.
  • 발행 주식 수는 약간 감소했으나 내부자의 경제적 노출은 변함이 없습니다.

Kaitlin M. Kestenberg-Messina, COO et SVP Conformité d'ADMA Biologics, a déposé un formulaire 4 pour un événement automatique de retenue d'actions le 24/07/2025. Le code de transaction F indique que 3 027 actions ordinaires ont été remises à la société au prix de 17,31 $ par action pour satisfaire aux obligations fiscales sur les salaires déclenchées par l'acquisition des unités d'actions restreintes (RSU) ; aucune action n'a été vendue sur le marché ouvert.

Après la transaction, le dirigeant détient effectivement 487 398 actions ADMA, comprenant 192 874 actions entièrement acquises et 294 524 RSU non acquises qui seront acquises trimestriellement jusqu'en 2029, sous réserve de la poursuite du service.

  • Le dépôt est un règlement fiscal de routine et ne reflète pas une réduction discrétionnaire de la propriété.
  • Le nombre d'actions en circulation est légèrement réduit, mais l'exposition économique des initiés reste inchangée.

Kaitlin M. Kestenberg-Messina, COO und SVP Compliance von ADMA Biologics, reichte am 24.07.2025 ein Formular 4 für ein automatisches Aktieneinbehaltungsereignis ein. Der Transaktionscode F zeigt, dass 3.027 Stammaktien zu je 17,31 $ an das Unternehmen zurückgegeben wurden, um die lohnsteuerlichen Verpflichtungen zu erfüllen, die durch die Vesting von Restricted Stock Units (RSUs) ausgelöst wurden; es wurden keine Aktien am offenen Markt verkauft.

Nach der Transaktion besitzt die Führungskraft wirtschaftlich 487.398 ADMA-Aktien, bestehend aus 192.874 vollständig unverfallbaren Aktien und 294.524 unverfallbaren RSUs, die bis 2029 vierteljährlich vesten, vorbehaltlich der fortgesetzten Dienstzeit.

  • Die Meldung ist eine routinemäßige Steuerabrechnung und stellt keine freiwillige Reduzierung des Eigentums dar.
  • Die Anzahl der ausstehenden Aktien wurde geringfügig reduziert, die wirtschaftliche Insider-Exponierung bleibt jedoch unverändert.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Kestenberg-Messina Kaitlin M.

(Last) (First) (Middle)
C/O ADMA BIOLOGICS, INC.
5800 PARK OF COMMERCE BLVD. NW

(Street)
BOCA RATON FL 33487

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
COO and SVP, Compliance
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/24/2025 F 3,027(1) D $17.31 487,398(2)(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
2. Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 144,240 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 15,000 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date;
3. (continued from footnote 2) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 192,874 shares of common stock directly owned by the reporting person, which includes the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
/s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What type of transaction did ADMA COO Kestenberg-Messina report?

A code F transaction—shares withheld by the company to cover RSU tax obligations.

How many ADMA shares were withheld for taxes?

The filing shows 3,027 common shares withheld at $17.31 each.

Does this Form 4 indicate an open-market sale?

No. Code F denotes a non-discretionary tax withholding, not an open-market sale.

What is the insider’s total ADMA ownership after the transaction?

Kestenberg-Messina now beneficially owns 487,398 shares, including unvested RSUs.

Are there any upcoming vesting schedules mentioned?

Yes. RSUs granted in 2022-2025 vest quarterly over four-year periods, contingent on continued service.
Adma Biologics

NASDAQ:ADMA

ADMA Rankings

ADMA Latest News

ADMA Latest SEC Filings

ADMA Stock Data

4.44B
229.12M
2.64%
88.42%
6.01%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RAMSEY